Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 2Terminated 1

Sponsor Class

INDUSTRY 3OTHER 2

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2Thoracic 1Plasma cell 1Myeloid 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 121Melanoma 111Neoplasms 66Carcinoma, Renal Cell 60Colorectal Neoplasms 43Neoplasm Metastasis 39Squamous Cell Carcinoma of Head and Neck 36Stomach Neoplasms 35Carcinoma, Hepatocellular 33Carcinoma, Transitional Cell 27Lung Neoplasms 23Pancreatic Neoplasms 22Triple Negative Breast Neoplasms 21Ovarian Neoplasms 21Head and Neck Neoplasms 21Advanced Cancer 19Breast Neoplasms 17Urinary Bladder Neoplasms 15Small Cell Lung Carcinoma 14Kidney Neoplasms 13Recurrence 11Hodgkin Disease 11Uterine Cervical Neoplasms 10Skin Neoplasms 10Lymphoma 10Solid Tumor 9Mesothelioma 9Endometrial Neoplasms 9Carcinoma, Merkel Cell 9Carcinoma 9

Interventions

10-propargyl-10-deazaaminopterin 12Cyclophosphamide 8Prednisone 7belinostat 6Vincristine 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Doxorubicin 6Brentuximab Vedotin 5romidepsin 4mogamulizumab 4darinaparsin 4Vitamin B 12 4Gemcitabine 4Folic Acid 4selinexor 3denileukin diftitox 3Nivolumab 3Injections 3Bendamustine Hydrochloride 3tislelizumab 2tipifarnib 2tenalisib 2duvelisib 2Rituximab 2Lenalidomide 2HBI-8000 2Fenretinide 2E7777 fusion protein 2AFM13 2venetoclax 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Lymphoma, T-Cell, Peripheral × Nivolumab × Clear all
NCT05255601 2026-02-25

RELATIVITY-069

Bristol-Myers Squibb

Phase 1/2 Completed
5 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Extranodal NK-T-Cell

NCT01716806 2024-06-11

A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)

Seagen Inc.

Phase 2 Completed
131 enrolled 28 charts
Lymphoid

Hematologic Diseases, Hodgkin Disease, Lymphoma, Lymphoma, T-Cell, Peripheral

NCT02663518 2024-05-10

A Trial of PF-07901800 (TTI-621) for Patients With Hematologic Malignancies and Selected Solid Tumors

Pfizer

Phase 1 Terminated
249 enrolled 43 charts
DermatologicLymphoidMyeloidOther hematologic neoplasmPlasma cellThoracic

Hodgkin Disease, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡